Table 3 Clinical pathological parameters of patients and the chi-square test of the relation between clinical features and risk score
From: Development of a novel lipid metabolism-based risk score model in hepatocellular carcinoma patients
Clinical feature | N | Risk score | X2 | p | |
|---|---|---|---|---|---|
High risk n(%) | Low risk n(%) | ||||
Age |  |  |  | 66.60 | < 0.001 |
 > 65 | 276 | 65 (23.55 %) | 211 (76.45 %) |  |  |
 ≤ 65 | 192 | 117 (60.94 %) | 75 (39.06 %) |  |  |
Gender | Â | Â | Â | 0.38 | 0.54 |
 Male | 309 | 123 (39.81 %) | 186 (60.19 %) |  |  |
 Female | 160 | 59 (36.88 %) | 101 (63.13 %) |  |  |
Child pugh classification grade | Â | Â | Â | 2.41 | 0.12 |
 A | 271 | 103 (38.01 %) | 168 (61.99 %) |  |  |
 B–C | 33 | 8 (24.24 %) | 25 (75.76 %) |  |  |
Adjacent hepatic tissue inflammation | Â | Â | Â | 0.00 | 0.98 |
 Yes | 146 | 48 (32.88 %) | 98 (67.12 %) |  |  |
 No | 162 | 53 (32.72 %) | 109 (67.28 %) |  |  |
BMI | Â | Â | Â | 1.95 | 0.16 |
 ≥ 30 | 93 | 31 (33.33 %) | 62 (66.67 %) |  |  |
 < 30 | 324 | 134 (41.36 %) | 190 (58.64 %) |  |  |
Cirrhosis | Â | Â | Â | 0.23 | 0.63 |
 Yes | 93 | 27 (29.03 %) | 66 (70.97 %) |  |  |
 No | 119 | 31 (26.05 %) | 88 (73.95 %) |  |  |
Grade |  |  |  | 16.73 | < 0.001 |
 I–II | 295 | 94 (31.86 %) | 201 (68.14 %) |  |  |
 III–IV | 166 | 85 (51.20 %) | 81 (48.80 %) |  |  |
Stage | Â | Â | Â | 2.60 | 0.11 |
 I–II | 306 | 118 (38.56 %) | 188 (61.44 %) |  |  |
 III–IV | 112 | 53 (47.32 %) | 59 (52.68 %) |  |  |
Barcelona clinic liver cancer | Â | Â | Â | 0.14 | 0.71 |
 A–B | 370 | 144 (38.92 %) | 226 (61.08 %) |  |  |
 C–D | 31 | 11 (35.48 %) | 20 (64.52 %) |  |  |
Neoadjuvant treatment | Â | Â | Â | 1.27 | 0.26 |
 Yes | 2 | 0 (0.00 %) | 2 (100.00 %) |  |  |
 No | 467 | 182 (38.97 %) | 285 (61.03 %) |  |  |
Radiation therapy | Â | Â | Â | 0.14 | 0.71 |
 Yes | 9 | 3 (33.33 %) | 6 (66.67 %) |  |  |
 No | 372 | 147 (39.52 %) | 225 (60.48 %) |  |  |
Person neoplasm cancer status | Â | Â | Â | 1.32 | 0.25 |
 Tumor free | 195 | 70 (35.90 %) | 125 (64.10 %) |  |  |
 With tumor | 165 | 69 (41.82 %) | 96 (58.18 %) |  |  |
Relative family cancer history | Â | Â | Â | 6.51 | 0.01 |
 Yes | 162 | 49 (30.25%) | 113 (69.75 %) |  |  |
 No | 248 | 106 (42.74%) | 142 (57.26 %) |  |  |